Back to Search Start Over

Xeris Biopharma announces positive results from phase 2 study of investigational XeriSol-formulated once-weekly SC levothyroxine to treat hypothyroidism

Source :
PharmaBiz. June 1, 2024
Publication Year :
2024

Abstract

Xeris Biopharma Holdings, Inc., a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, announced topline results from its recently [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
PharmaBiz
Publication Type :
Periodical
Accession number :
edsgcl.795987438